Fusing nature
with science
Company
Izun Pharmaceuticals Corporation’s platform technology develops highly effective healthcare solutions for multiple unmet medical conditions. The company identifies and harnesses the therapeutic elements of natural plants and utilizes proprietary extraction processes and analytics to optimize the compounds involved, while maintaining the safety profile of the plant.
These technologies provide a more therapeutically effective natural product, combined with the security of an excellent safety profile. The extracts are carefully monitored, using chemical analysis and bioassays, from plant harvest to the finished product. The products capture the beneficial activity of each component, capitalizing on synergistic interactions that emerge from the unique combination within.
Izun products are developed and manufactured to the highest quality and regulatory standards, including FDA clearance where needed.
Izun has a strong patent and trademark portfolio to support the products.
Products
Periodontal Disease
PeriActive® is a clinically proven, plant-based mouthwash with exceptional anti-inflammatory, antibacterial, and wound-healing properties that provides treatment for the underlying causes of
gingivitis and periodontitis, common chronic inflammatory conditions of the mouth. The CDC estimates that 50% of American adults over the age of 35 have significant periodontal disease. The prevalence increases to over 70% in people aged over 65 years. PeriActive® is sold to both B2B and B2C.
Women’s Health
Izun is developing a groundbreaking treatment for Genitourinary Syndrome of Menopause (GSM), also known as Vulvovaginal Atrophy, Vaginal Atrophy and Atrophic Vaginitis. GSM develops when women’s estrogen production decreases due to menopause or as a side effect of drug therapy. Low estrogen levels (hypo-estrogenemia) result in vaginal tissue that is dry, thin and inflamed. Women who suffer from GSM report significant vaginal pain, dryness, urinary incontinence and extremely painful intercourse (Dyspareunia). GSM significantly impacts the quality of life of over 65 million women in the United States
Chronic Wound Care
CURASITE® is a highly effective topical treatment for all chronic wounds, including diabetic foot ulcers (DFU). CURASITE® is FDA cleared as a first- line therapy for the management of chronic
wounds.
Oncology Support
Our leading candidate, IZN-6N4, is designed to prevent and treat Oral Mucositis in all cancer patients treated with chemotherapy and/or radiation therapy. Oral Mucositis, which occurs in over 50% of these patients, is characterized by the painful and debilitating ulcerated sores that develop in the mouth and throat during cancer treatment.
Team
Jonathan Kalman, CEO
Serial entrepreneur, with track record of launching, building, and selling successful businesses.
-
Early investor and board member across early-stage technology companies with a focus on biopharma and medical devices.
-
Three successful M&A transactions to international corporations for amounts ranging from $70M to $1.1BB.
Dr. William Levine, CSO
-
DDS degree with specialty training in Periodontics from Columbia University.
-
Founder of Izun Pharmaceuticals, a biopharmaceutical company specializing in Botanical Medicine.
-
Diplomate of the American Board of Periodontology.
-
Member of Scientific Board of companies focused on Robotic Surgery and Oral Diagnostic technologies.
Les Kraus, CFO
-
CPA with 40+ years of operational and financial experience covering industrial, retail and wholesale businesses.
-
Former CFO of Australia’s largest menswear retailer, where he managed two sale processes to private equity firms.
Dr Amy Rosenbluh, Director of Production & Laboratory Manager
-
Master’s degree from Harvard University and Ph.D. from Tel Aviv University, with post-doctoral fellowships at both Stanford University and the Weizmann Institute.
-
Vast experience in academic research and management, both in academia and in the private sector.
Contact us
Corporate Headquarters
1177 6th Avenue
5th floor
New York, NY 10036
1-800-956-2595
R&D Headquarters
11 Kiryat Mada Street
3rd floor
Har Hotzvim, Jerusalem 9777611
972-72-245-8950